Phaseline

Companies › YS Life Science

YS Life Science: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YSBP
Prostaglandin F (FP) receptor agonist
PTGFRPhase 3Primary Open Angle Glaucoma (POAG)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07661329YSBPPhase 3Primary Open Angle Glaucoma (POAG)OphthalmologyNov 2027

Targets

PTGFR (1)

Companies with the same targets

SpyGlass Pharma Glaukos Santen Pharmaceutical Triple Hair

Companies built like this

Santen Pharmaceutical SpyGlass Pharma Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.